ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tzelepis, G
Right arrow Articles by Fulambarker, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tzelepis, G
Right arrow Articles by Fulambarker, A
Eur Respir J 1996; 9: 100-103
Copyright © ERS Journals Ltd 1996

Clinical Trial

Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease

G Tzelepis, S Komanapolli, D Tyler, D Vega, and A Fulambarker

We assessed the bronchodilating effect of glycopyrrolate (GP) and compared it with that of metaproterenol (MP), alone and in combination (GP+MP), in patients with chronic obstructive pulmonary disease (COPD). In a double-blind study, 11 patients (aged (mean +/- SD) 69 +/- 6 yrs; forced expiratory volume in one second (FEV1) 1.2 +/- 0.4 L) with stable COPD inhaled nebulized GP 1.0 mg, MP 15 mg, or GP 1.0 mg+MP 15 mg. Spirometry was performed before inhalation and at hourly intervals for 8 h after inhalation. It was found that GP produced a bronchodilating effect that was about equal to that of MP but lasted longer (8 vs 5 h). The combination of GP and MP produced a bronchodilating effect that was greater than that of either drug alone and was evident mostly during the effect of MP. The mean peak percentage improvement in FEV1 over baseline was 35% for GP+MP and 25% for either drug alone. These data suggest that nebulized glycopyrrolate is an effective bronchodilator in some patients with chronic obstructive pulmonary disease. Concurrent administration of glycopyrrolate and metaproterenol produces additional bronchodilation that is primarily apparent during the bronchodilator effect of metaproterenol.


This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
A. R. Tait, C. Burke, T. Voepel-Lewis, D. Chiravuri, D. Wagner, and S. Malviya
Glycopyrrolate Does Not Reduce the Incidence of Perioperative Adverse Events in Children with Upper Respiratory Tract Infections
Anesth. Analg., February 1, 2007; 104(2): 265 - 270.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
J. F. Donohue
Combination Therapy for Chronic Obstructive Pulmonary Disease: Clinical Aspects
Proceedings of the ATS, November 1, 2005; 2(4): 272 - 281.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
T. T. Hansel, H. Neighbour, E. M. Erin, A. J. Tan, R. C. Tennant, J. G. Maus, and P. J. Barnes
Glycopyrrolate Causes Prolonged Bronchoprotection and Bronchodilatation in Patients With Asthma
Chest, October 1, 2005; 128(4): 1974 - 1979.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the European Respiratory Society.